LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study

Donato Alarcón-Segovia, James A. Tumlin, Richard A. Furie, James D. McKay, Mario H. Cardiel, Vibeke Strand, Robert G. Bagin, Matthew D. Linnik, Bonnie Hepburn, Jacob Aelion, Gerald B. Appel, Cynthia Aranow, Stanley Ballou, Michael Becker, Nancy J. Becker, H. Michael Belmont, Jill P. Buyon, Anthony Bohan, William G. Brelsford, Nancy L. CarteronMary E. Cronin, Raphael J. DeHoratius, Luis R. Espinoza, Mark C. Genovese, Gary Gilkeson, Antonio Gil-Aguado, Oscar Gluck, Jose L. Granda, Maria Hill, Paul Howard, Miguel Ingelmo, Kenneth C. Kalunian, Gary M. Kammer, Keith Kanik, Stanley Kaplan, Howard M. Kenney, Neil A. Kurtzman, Robert G. Lahita, Michael Liebling, Jill Suzanne Lindberg, Susan Manzi, Joan T. Merrill, Larry W. Moreland, C. Michael Neuwelt, Michelle A. Petri, Rosalind Ramsey-Goldman, Steven G. Rosenblatt, Naomi Rothfield, John T. Schousboe, K. Lea Sewell, Yvonne Sherrer, Douglas B. Smith, Bruce S. Spinowitz, Roland M. Staub, Steven Stern, Jon T. Stevenson, Ronald Van Vollenhoven, John Varga, Miguel Vilardell-Tarres, Daniel J. Wallace

Research output: Contribution to journalArticle

239 Citations (Scopus)

Abstract

Objective. To determine whether LJP 394 delays or prevents renal flare in patients with systemic lupus erythematosus (SLE) and a history of renal disease. Methods. In a 76-week, double-blind, placebo-controlled study, 230 SLE patients were randomized to receive 16 weekly doses of 100 mg of LJP 394 or placebo, followed by alternating 8-week drug holidays and 12 weekly doses of 50 mg of LJP 394 or placebo. An assay measuring the affinity of the serum IgG fraction for the DNA epitope of LJP 394 identified a high-affinity population of patients (189 of 213 patients; 89% taking LJP 394 and 90% taking placebo). Analyses were performed on both the intent-to-treat population and the high-affinity population. Results. Anti-double-stranded DNA antibodies decreased and C3 levels tended to increase during treatment with LJP 394. In the intent-to-treat population, the time to renal flare was not significantly different between treatment groups, but patients taking LJP 394 had a longer time to institution of high-dose cortico-steroids and/or cyclophosphamide (HDCC) and required 41% fewer treatments with HDCC. In the high-affinity population, the LJP 394 group experienced a longer time to renal flare, 67% fewer renal flares, longer time to institution of HDCC, and 62% fewer HDCC treatments compared with the placebo group. In patients with serum creatinine levels ≥1.5 mg/dl at study entry, those taking LJP 394 had 50% fewer renal flares; no renal flares were observed in the high-affinity group taking LJP 394. Serious adverse events were observed in 25 of the 114 LJP 394-treated patients (21.9%) and 34 of the 116 placebo-treated patients (29.3%). Conclusion. Treatment with LJP 394 in patients with high-affinity antibodies to its DNA epitope prolonged the time to renal flare, decreased the number of renal flares, and required fewer HDCC treatments compared with placebo. The study drug appeared to be well tolerated.

Original languageEnglish (US)
Pages (from-to)442-454
Number of pages13
JournalArthritis and Rheumatism
Volume48
Issue number2
DOIs
StatePublished - Feb 1 2003
Externally publishedYes

Fingerprint

Systemic Lupus Erythematosus
Placebos
Kidney
Cyclophosphamide
Steroids
Population
abetimus
Epitopes
DNA
Therapeutics
Holidays
Antibody Affinity
Serum
Pharmaceutical Preparations
Creatinine
Immunoglobulin G
Antibodies

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus : Results from a randomized, double-blind, placebo-controlled study. / Alarcón-Segovia, Donato; Tumlin, James A.; Furie, Richard A.; McKay, James D.; Cardiel, Mario H.; Strand, Vibeke; Bagin, Robert G.; Linnik, Matthew D.; Hepburn, Bonnie; Aelion, Jacob; Appel, Gerald B.; Aranow, Cynthia; Ballou, Stanley; Becker, Michael; Becker, Nancy J.; Belmont, H. Michael; Buyon, Jill P.; Bohan, Anthony; Brelsford, William G.; Carteron, Nancy L.; Cronin, Mary E.; DeHoratius, Raphael J.; Espinoza, Luis R.; Genovese, Mark C.; Gilkeson, Gary; Gil-Aguado, Antonio; Gluck, Oscar; Granda, Jose L.; Hill, Maria; Howard, Paul; Ingelmo, Miguel; Kalunian, Kenneth C.; Kammer, Gary M.; Kanik, Keith; Kaplan, Stanley; Kenney, Howard M.; Kurtzman, Neil A.; Lahita, Robert G.; Liebling, Michael; Lindberg, Jill Suzanne; Manzi, Susan; Merrill, Joan T.; Moreland, Larry W.; Neuwelt, C. Michael; Petri, Michelle A.; Ramsey-Goldman, Rosalind; Rosenblatt, Steven G.; Rothfield, Naomi; Schousboe, John T.; Sewell, K. Lea; Sherrer, Yvonne; Smith, Douglas B.; Spinowitz, Bruce S.; Staub, Roland M.; Stern, Steven; Stevenson, Jon T.; Van Vollenhoven, Ronald; Varga, John; Vilardell-Tarres, Miguel; Wallace, Daniel J.

In: Arthritis and Rheumatism, Vol. 48, No. 2, 01.02.2003, p. 442-454.

Research output: Contribution to journalArticle

Alarcón-Segovia, D, Tumlin, JA, Furie, RA, McKay, JD, Cardiel, MH, Strand, V, Bagin, RG, Linnik, MD, Hepburn, B, Aelion, J, Appel, GB, Aranow, C, Ballou, S, Becker, M, Becker, NJ, Belmont, HM, Buyon, JP, Bohan, A, Brelsford, WG, Carteron, NL, Cronin, ME, DeHoratius, RJ, Espinoza, LR, Genovese, MC, Gilkeson, G, Gil-Aguado, A, Gluck, O, Granda, JL, Hill, M, Howard, P, Ingelmo, M, Kalunian, KC, Kammer, GM, Kanik, K, Kaplan, S, Kenney, HM, Kurtzman, NA, Lahita, RG, Liebling, M, Lindberg, JS, Manzi, S, Merrill, JT, Moreland, LW, Neuwelt, CM, Petri, MA, Ramsey-Goldman, R, Rosenblatt, SG, Rothfield, N, Schousboe, JT, Sewell, KL, Sherrer, Y, Smith, DB, Spinowitz, BS, Staub, RM, Stern, S, Stevenson, JT, Van Vollenhoven, R, Varga, J, Vilardell-Tarres, M & Wallace, DJ 2003, 'LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study', Arthritis and Rheumatism, vol. 48, no. 2, pp. 442-454. https://doi.org/10.1002/art.10763
Alarcón-Segovia, Donato ; Tumlin, James A. ; Furie, Richard A. ; McKay, James D. ; Cardiel, Mario H. ; Strand, Vibeke ; Bagin, Robert G. ; Linnik, Matthew D. ; Hepburn, Bonnie ; Aelion, Jacob ; Appel, Gerald B. ; Aranow, Cynthia ; Ballou, Stanley ; Becker, Michael ; Becker, Nancy J. ; Belmont, H. Michael ; Buyon, Jill P. ; Bohan, Anthony ; Brelsford, William G. ; Carteron, Nancy L. ; Cronin, Mary E. ; DeHoratius, Raphael J. ; Espinoza, Luis R. ; Genovese, Mark C. ; Gilkeson, Gary ; Gil-Aguado, Antonio ; Gluck, Oscar ; Granda, Jose L. ; Hill, Maria ; Howard, Paul ; Ingelmo, Miguel ; Kalunian, Kenneth C. ; Kammer, Gary M. ; Kanik, Keith ; Kaplan, Stanley ; Kenney, Howard M. ; Kurtzman, Neil A. ; Lahita, Robert G. ; Liebling, Michael ; Lindberg, Jill Suzanne ; Manzi, Susan ; Merrill, Joan T. ; Moreland, Larry W. ; Neuwelt, C. Michael ; Petri, Michelle A. ; Ramsey-Goldman, Rosalind ; Rosenblatt, Steven G. ; Rothfield, Naomi ; Schousboe, John T. ; Sewell, K. Lea ; Sherrer, Yvonne ; Smith, Douglas B. ; Spinowitz, Bruce S. ; Staub, Roland M. ; Stern, Steven ; Stevenson, Jon T. ; Van Vollenhoven, Ronald ; Varga, John ; Vilardell-Tarres, Miguel ; Wallace, Daniel J. / LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus : Results from a randomized, double-blind, placebo-controlled study. In: Arthritis and Rheumatism. 2003 ; Vol. 48, No. 2. pp. 442-454.
@article{5424fd42f8d94c85a9b66fb56c899aa3,
title = "LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study",
abstract = "Objective. To determine whether LJP 394 delays or prevents renal flare in patients with systemic lupus erythematosus (SLE) and a history of renal disease. Methods. In a 76-week, double-blind, placebo-controlled study, 230 SLE patients were randomized to receive 16 weekly doses of 100 mg of LJP 394 or placebo, followed by alternating 8-week drug holidays and 12 weekly doses of 50 mg of LJP 394 or placebo. An assay measuring the affinity of the serum IgG fraction for the DNA epitope of LJP 394 identified a high-affinity population of patients (189 of 213 patients; 89{\%} taking LJP 394 and 90{\%} taking placebo). Analyses were performed on both the intent-to-treat population and the high-affinity population. Results. Anti-double-stranded DNA antibodies decreased and C3 levels tended to increase during treatment with LJP 394. In the intent-to-treat population, the time to renal flare was not significantly different between treatment groups, but patients taking LJP 394 had a longer time to institution of high-dose cortico-steroids and/or cyclophosphamide (HDCC) and required 41{\%} fewer treatments with HDCC. In the high-affinity population, the LJP 394 group experienced a longer time to renal flare, 67{\%} fewer renal flares, longer time to institution of HDCC, and 62{\%} fewer HDCC treatments compared with the placebo group. In patients with serum creatinine levels ≥1.5 mg/dl at study entry, those taking LJP 394 had 50{\%} fewer renal flares; no renal flares were observed in the high-affinity group taking LJP 394. Serious adverse events were observed in 25 of the 114 LJP 394-treated patients (21.9{\%}) and 34 of the 116 placebo-treated patients (29.3{\%}). Conclusion. Treatment with LJP 394 in patients with high-affinity antibodies to its DNA epitope prolonged the time to renal flare, decreased the number of renal flares, and required fewer HDCC treatments compared with placebo. The study drug appeared to be well tolerated.",
author = "Donato Alarc{\'o}n-Segovia and Tumlin, {James A.} and Furie, {Richard A.} and McKay, {James D.} and Cardiel, {Mario H.} and Vibeke Strand and Bagin, {Robert G.} and Linnik, {Matthew D.} and Bonnie Hepburn and Jacob Aelion and Appel, {Gerald B.} and Cynthia Aranow and Stanley Ballou and Michael Becker and Becker, {Nancy J.} and Belmont, {H. Michael} and Buyon, {Jill P.} and Anthony Bohan and Brelsford, {William G.} and Carteron, {Nancy L.} and Cronin, {Mary E.} and DeHoratius, {Raphael J.} and Espinoza, {Luis R.} and Genovese, {Mark C.} and Gary Gilkeson and Antonio Gil-Aguado and Oscar Gluck and Granda, {Jose L.} and Maria Hill and Paul Howard and Miguel Ingelmo and Kalunian, {Kenneth C.} and Kammer, {Gary M.} and Keith Kanik and Stanley Kaplan and Kenney, {Howard M.} and Kurtzman, {Neil A.} and Lahita, {Robert G.} and Michael Liebling and Lindberg, {Jill Suzanne} and Susan Manzi and Merrill, {Joan T.} and Moreland, {Larry W.} and Neuwelt, {C. Michael} and Petri, {Michelle A.} and Rosalind Ramsey-Goldman and Rosenblatt, {Steven G.} and Naomi Rothfield and Schousboe, {John T.} and Sewell, {K. Lea} and Yvonne Sherrer and Smith, {Douglas B.} and Spinowitz, {Bruce S.} and Staub, {Roland M.} and Steven Stern and Stevenson, {Jon T.} and {Van Vollenhoven}, Ronald and John Varga and Miguel Vilardell-Tarres and Wallace, {Daniel J.}",
year = "2003",
month = "2",
day = "1",
doi = "10.1002/art.10763",
language = "English (US)",
volume = "48",
pages = "442--454",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus

T2 - Results from a randomized, double-blind, placebo-controlled study

AU - Alarcón-Segovia, Donato

AU - Tumlin, James A.

AU - Furie, Richard A.

AU - McKay, James D.

AU - Cardiel, Mario H.

AU - Strand, Vibeke

AU - Bagin, Robert G.

AU - Linnik, Matthew D.

AU - Hepburn, Bonnie

AU - Aelion, Jacob

AU - Appel, Gerald B.

AU - Aranow, Cynthia

AU - Ballou, Stanley

AU - Becker, Michael

AU - Becker, Nancy J.

AU - Belmont, H. Michael

AU - Buyon, Jill P.

AU - Bohan, Anthony

AU - Brelsford, William G.

AU - Carteron, Nancy L.

AU - Cronin, Mary E.

AU - DeHoratius, Raphael J.

AU - Espinoza, Luis R.

AU - Genovese, Mark C.

AU - Gilkeson, Gary

AU - Gil-Aguado, Antonio

AU - Gluck, Oscar

AU - Granda, Jose L.

AU - Hill, Maria

AU - Howard, Paul

AU - Ingelmo, Miguel

AU - Kalunian, Kenneth C.

AU - Kammer, Gary M.

AU - Kanik, Keith

AU - Kaplan, Stanley

AU - Kenney, Howard M.

AU - Kurtzman, Neil A.

AU - Lahita, Robert G.

AU - Liebling, Michael

AU - Lindberg, Jill Suzanne

AU - Manzi, Susan

AU - Merrill, Joan T.

AU - Moreland, Larry W.

AU - Neuwelt, C. Michael

AU - Petri, Michelle A.

AU - Ramsey-Goldman, Rosalind

AU - Rosenblatt, Steven G.

AU - Rothfield, Naomi

AU - Schousboe, John T.

AU - Sewell, K. Lea

AU - Sherrer, Yvonne

AU - Smith, Douglas B.

AU - Spinowitz, Bruce S.

AU - Staub, Roland M.

AU - Stern, Steven

AU - Stevenson, Jon T.

AU - Van Vollenhoven, Ronald

AU - Varga, John

AU - Vilardell-Tarres, Miguel

AU - Wallace, Daniel J.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Objective. To determine whether LJP 394 delays or prevents renal flare in patients with systemic lupus erythematosus (SLE) and a history of renal disease. Methods. In a 76-week, double-blind, placebo-controlled study, 230 SLE patients were randomized to receive 16 weekly doses of 100 mg of LJP 394 or placebo, followed by alternating 8-week drug holidays and 12 weekly doses of 50 mg of LJP 394 or placebo. An assay measuring the affinity of the serum IgG fraction for the DNA epitope of LJP 394 identified a high-affinity population of patients (189 of 213 patients; 89% taking LJP 394 and 90% taking placebo). Analyses were performed on both the intent-to-treat population and the high-affinity population. Results. Anti-double-stranded DNA antibodies decreased and C3 levels tended to increase during treatment with LJP 394. In the intent-to-treat population, the time to renal flare was not significantly different between treatment groups, but patients taking LJP 394 had a longer time to institution of high-dose cortico-steroids and/or cyclophosphamide (HDCC) and required 41% fewer treatments with HDCC. In the high-affinity population, the LJP 394 group experienced a longer time to renal flare, 67% fewer renal flares, longer time to institution of HDCC, and 62% fewer HDCC treatments compared with the placebo group. In patients with serum creatinine levels ≥1.5 mg/dl at study entry, those taking LJP 394 had 50% fewer renal flares; no renal flares were observed in the high-affinity group taking LJP 394. Serious adverse events were observed in 25 of the 114 LJP 394-treated patients (21.9%) and 34 of the 116 placebo-treated patients (29.3%). Conclusion. Treatment with LJP 394 in patients with high-affinity antibodies to its DNA epitope prolonged the time to renal flare, decreased the number of renal flares, and required fewer HDCC treatments compared with placebo. The study drug appeared to be well tolerated.

AB - Objective. To determine whether LJP 394 delays or prevents renal flare in patients with systemic lupus erythematosus (SLE) and a history of renal disease. Methods. In a 76-week, double-blind, placebo-controlled study, 230 SLE patients were randomized to receive 16 weekly doses of 100 mg of LJP 394 or placebo, followed by alternating 8-week drug holidays and 12 weekly doses of 50 mg of LJP 394 or placebo. An assay measuring the affinity of the serum IgG fraction for the DNA epitope of LJP 394 identified a high-affinity population of patients (189 of 213 patients; 89% taking LJP 394 and 90% taking placebo). Analyses were performed on both the intent-to-treat population and the high-affinity population. Results. Anti-double-stranded DNA antibodies decreased and C3 levels tended to increase during treatment with LJP 394. In the intent-to-treat population, the time to renal flare was not significantly different between treatment groups, but patients taking LJP 394 had a longer time to institution of high-dose cortico-steroids and/or cyclophosphamide (HDCC) and required 41% fewer treatments with HDCC. In the high-affinity population, the LJP 394 group experienced a longer time to renal flare, 67% fewer renal flares, longer time to institution of HDCC, and 62% fewer HDCC treatments compared with the placebo group. In patients with serum creatinine levels ≥1.5 mg/dl at study entry, those taking LJP 394 had 50% fewer renal flares; no renal flares were observed in the high-affinity group taking LJP 394. Serious adverse events were observed in 25 of the 114 LJP 394-treated patients (21.9%) and 34 of the 116 placebo-treated patients (29.3%). Conclusion. Treatment with LJP 394 in patients with high-affinity antibodies to its DNA epitope prolonged the time to renal flare, decreased the number of renal flares, and required fewer HDCC treatments compared with placebo. The study drug appeared to be well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0037331980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037331980&partnerID=8YFLogxK

U2 - 10.1002/art.10763

DO - 10.1002/art.10763

M3 - Article

C2 - 12571854

AN - SCOPUS:0037331980

VL - 48

SP - 442

EP - 454

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 2

ER -